December 28, 2016 “VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy.
January 28, 2016 Adoption of GeneStrat by oncologists is helping to drive greater adoption of VeriStrat, Biodesix’s proteomic test for assessing a patient’s prognosis and predicting response to drug treatment.
September 4, 2015
“Biodesix discovers and commercializes cancer tests that help patients and their doctors make more informed decisions about treatment based on a patient’s unique molecular profile….” Read more at inc.com
Google+ Twitter Youtube
TERMS and CONDITIONS
This site is for informational purposes only and is not intended to be a ... Read more
May 21, 2015
Diagnostic Test Reveals Actionable Mutations; Results Returned Within 72 Hours
Biodesix, Inc. today announced the launch of GeneStrat™, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC). The blood test results are available within 72 hours, providing physicians actionable diagnostic information prior to making treatment decisions. GeneStrat ... Read more
May 12, 2015
Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from United Healthcare (NYSE: UNH), one of the largest commercial insurance company in the US, with a published 44.7 million covered lives. In its Medical Policy (#2015T0535EE), United Healthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung ... Read more
April 9, 2015
The VeriStrat proteomic test, when used to help guide treatment of patients with advanced non-small cell lung cancer, improves overall survival and decreases medical costs in the U.S. payer system, said a study published recently in the journal Lung Cancer.
“Systems of care are gearing up for bundled payment models in oncology. With the evolving changes in ... Read more